Kurser indlæses...
Prognose
| Køb |
1 |
| Behold |
0 |
| Sælg |
0 |
Nyheder Til nyhedsfeedet
Genprex reports quarterly loss per share of $9.40
Genprex published on August 14, 2026 the results for the quarter ended June 30, 2026 and reported a loss per share of $9.40. For the prior year, EPS was -$187,000 per share. » Mere på finanzen.net
Genprex partners with Roche Diagnostics to validate TROP2 biomarker in NSCLC
Genprex announced a collaboration with Roche Diagnostics to validate biomarkers for patient selection in NSCLC studies using Roche’s TROP2 antibody. Preclinical and clinical data from Genprex show that high TROP2 H-scores and low PTEN H-scores predict response and longer progression-free survival. Roche will conduct the assay validation with the antibody, and Genprex plans to use the same antibody in its validation studies, which are expected to be completed by the end of 2026; integration into the clinical NSCLC program is to follow. The announcement lifted Genprex shares by about 3%. » Mere på de.investing.com
Virksomhedstal
| (EUR) | juni 2026 | |
|---|---|---|
| Omsætning | 0 | - |
| Bruttofortjeneste | 0 | - |
| Nettoresultat | -3,9 mio. | 1,75 % |
| EBITDA | -3,9 mio. | 1,72 % |
Fundamentale data
| Nøgletal | Værdi |
|---|---|
Markedsværdi | 1,46 mio. € |
Antal aktier | 504,94 t |
Højeste/laveste i 52 uger | 1.042,78 € - 2,85 € |
| Udbytte | Nej |
Beta | -0,93 |
P/E (PE Ratio) | -0,02 |
PEG (PEG Ratio) | 0,00 |
K/I (PB Ratio) | 0,11 |
P/S (PS Ratio) | 0,00 |
Virksomhedsprofil
| Navn | Genprex |
| CEO | Ryan Confer |
| Medarbejdere | 13 |
